Which patients with AML in CR1 should be considered for an allogenic stem cell transplant
| Characteristic . | MRD after induction cycle 2 . | Estimated risk of relapse following consolidation with . | Maximal tolerated NRM prognostic scores for allogeneic SCT to be considered . | ||
|---|---|---|---|---|---|
| Intensive chemotherapy, % . | Allogeneic SCT, % . | HCT-CI score . | 2-year NRM, % . | ||
| Favorable | Negative | 30-40 | 15-20 | NA (not advisable to proceed) | |
| Positive | 70-80 | 30-40 | ≤3-4 | <35 | |
| Intermediate | Negative | 50-60 | 25-30 | ≤2 | <20 |
| Positive | 70-80 | 30-35 | ≤3-4 | <35 | |
| Adverse | NA | >90 | 40 | ≤3-4 | <35 |
| Characteristic . | MRD after induction cycle 2 . | Estimated risk of relapse following consolidation with . | Maximal tolerated NRM prognostic scores for allogeneic SCT to be considered . | ||
|---|---|---|---|---|---|
| Intensive chemotherapy, % . | Allogeneic SCT, % . | HCT-CI score . | 2-year NRM, % . | ||
| Favorable | Negative | 30-40 | 15-20 | NA (not advisable to proceed) | |
| Positive | 70-80 | 30-40 | ≤3-4 | <35 | |
| Intermediate | Negative | 50-60 | 25-30 | ≤2 | <20 |
| Positive | 70-80 | 30-35 | ≤3-4 | <35 | |
| Adverse | NA | >90 | 40 | ≤3-4 | <35 |
NA, not advisable; NRM, non-relapse mortality.